Skip to main content

Articles

Page 1 of 14

  1. The population of older adults continues to grow in Iran, with pharmaceutical costs as a leading driver of household health-related costs. The present study was conducted to estimate the out-of-pocket pharmace...

    Authors: Mehran Faraji, Tahereh Sharifi, Saeed Mohammad-pour, Javad Javan-Noughabi, Ali Aboutorabi, Shaghayegh yousefi and Mihajlo Jakovljevic
    Citation: Cost Effectiveness and Resource Allocation 2024 22:15
  2. The study aimed to examine the direct medical cost and impact of tocilizumab (TOZ) versus adalimumab (ADM) and etanercept (ETC) on reducing the levels of two inflammatory markers (e.g., C-reactive protein (CRP...

    Authors: Areej S. Albahdal, Amjad M. Alotaibi, Miteb A. Alanazi, Norah Abanmy, Monira Alwhaibi and Yazed AlRuthia
    Citation: Cost Effectiveness and Resource Allocation 2024 22:14
  3. Many individuals suffer from normal tension glaucoma (NTG) in China. This study utilized Markov models to evaluate the cost-utility of applying many medications and surgery for mild-stage NTG when disease prog...

    Authors: Di Song and Liwen Wang
    Citation: Cost Effectiveness and Resource Allocation 2024 22:13
  4. There is limited evidence-informed guidance on TISP processes for countries where health technology assessment (HTA) is in a nascent phase. We aimed to explore the range of topic identification, selection and ...

    Authors: Julia Bidonde, Vigdis Lauvrak, Aparna Ananthakrishnan, Pritaporn Kingkaew and Elizabeth F. Peacocke
    Citation: Cost Effectiveness and Resource Allocation 2024 22:12
  5. The treatment of hepatitis C has entered the pan-genotypic era, but the effectiveness is not good for the genotype 3b patients who have a large proportion in China. The guidelines for hepatitis C recommend the...

    Authors: Yusi Tu, Xiangyan Tang, Dachuang Zhou, Hanqiao Shao, Leyi Liang and Wenxi Tang
    Citation: Cost Effectiveness and Resource Allocation 2024 22:11
  6. Preference elicitation is widely used within health economic evaluations to inform coverage decisions. However, coverage decisions involve questions of social justice and it is unclear what role empirical evid...

    Authors: Wolf Rogowski and Jürgen John
    Citation: Cost Effectiveness and Resource Allocation 2024 22:10
  7. Combined serplulimab and chemotherapy demonstrated improved clinical survival outcomes in patients with advanced esophageal squamous cell carcinoma (ESCC) and PD-L1 combined positive scores (CPS) ≥ 1. The pres...

    Authors: Jiahui Li, Chaoqun Xu and Suyun Yuan
    Citation: Cost Effectiveness and Resource Allocation 2024 22:8
  8. Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC). We aimed to assess the cost-effectiv...

    Authors: Jing Nie, Huina Wu, Qian Wu, Lihui Liu, Ke Tang, Shuo Wang and Jiyong Wu
    Citation: Cost Effectiveness and Resource Allocation 2024 22:6
  9. Add-on therapy with tiotropium was cost-effective when added to usual care in patients who remain uncontrolled despite treatment with medium or high-dose ICS/LABA in a middle-income country.

    Authors: Jefferson Antonio Buendía and Diana Guerrero Patiño
    Citation: Cost Effectiveness and Resource Allocation 2024 22:4
  10. Human communities suffered a vast socioeconomic burden in dealing with the pandemic of coronavirus disease 2019 (COVID-19) globally. Real-word data about these burdens can inform governments about evidence-bas...

    Authors: Majid Nakhaee, Masoud Khandehroo and Reza Esmaeili
    Citation: Cost Effectiveness and Resource Allocation 2024 22:3
  11. Access to convenient quality healthcare at all times is considered a basic human right; however, many countries are still striving to achieve this goal for their populations. The persistent rise in healthcare ...

    Authors: Mohammed Khaled Al-Hanawi and Naseem Al Rahahleh
    Citation: Cost Effectiveness and Resource Allocation 2024 22:2
  12. Maternal and neonatal mortality in low- and middle-income countries is frequently caused by inadequate management of obstetric and neonatal complications and a shortage of skilled health workers. The availabil...

    Authors: Chakib Boukhalfa, Brahim Ouakhzan, Hanane Masbah, Leila Acharai and Saad Zbiri
    Citation: Cost Effectiveness and Resource Allocation 2024 22:1
  13. In China, the healthcare financing structure involves multiple parties, including the government, society and individuals. Medicare Fund is an important way for the Government and society to reduce the burden ...

    Authors: Wenqing Wu, Shujie Long, Arcadio A. Cerda, Leidy Y. Garcia and Mihajlo Jakovljevic
    Citation: Cost Effectiveness and Resource Allocation 2023 21:97
  14. The value of a life is regularly monetised by government departments for informing resource allocation. Guidance documents indicate how economic evaluation should be conducted, often specifying precise values ...

    Authors: Patricia Cubi-Molla, David Mott, Nadine Henderson, Bernarda Zamora, Mendel Grobler and Martina Garau
    Citation: Cost Effectiveness and Resource Allocation 2023 21:96
  15. Psoriasis, an immune-mediated chronic inflammatory disease primarily affecting skin and joints, has varying prevalence rates globally. It manifests in five types, with chronic plaque psoriasis being the most c...

    Authors: Yazed AlRuthia, Almaha H. Alfakhri, Ibtisam Alharbi, Fadi Ali Alghamdi, Miteb A. Alanazi, Abdullah Abdulrahman Alrabiah, Anwar Abdulrazzag Alsouan, Abdulrahman Abdullah Alshaikh and Majed Ali Almasaoud
    Citation: Cost Effectiveness and Resource Allocation 2023 21:95
  16. Although the treatment for end-stage renal disease (ESRD) under Nigeria’s National Health Insurance Authority is haemodialysis (HD), the cost of managing ESRD is understudied in Nigeria. Therefore, this study ...

    Authors: Yakubu Adole Agada-Amade, Daniel Chukwuemeka Ogbuabor, Ejemai Eboreime and Obinna Emmanuel Onwujekwe
    Citation: Cost Effectiveness and Resource Allocation 2023 21:94
  17. According to the Chinese guidelines for lipid management (2023), evolocumab in combination with statins was recommended as secondary prevention of cardiovascular disease. However, because of the variation in t...

    Authors: Yuansheng Wan, Jinyu Liu, Xiaolian Zhan, Yu Zhang and Ruxu You
    Citation: Cost Effectiveness and Resource Allocation 2023 21:93
  18. The aim of this article is to evaluate the cost-effectiveness of abemaciclib plus endocrine therapy (ABE + ET) vs. ET as adjuvant treatment for high-risk hormone receptor-positive and human epidermal growth fa...

    Authors: Qiran Wei, YuTing Xu, Wei Liu and Xin Guan
    Citation: Cost Effectiveness and Resource Allocation 2023 21:91
  19. This study investigates Iranian men’s willingness to pay (WTP) for prostate cancer (PCa) screening and influencing factor, along with the impact of information.

    Authors: Hiro Farabi, Najmeh Moradi, Aziz Ahmadzadeh, Seyed Mohammad Kazem Agamir, Abdolreza Mohammadi and Aziz Rezapour
    Citation: Cost Effectiveness and Resource Allocation 2023 21:89
  20. To investigate the cost-effectiveness of using Implant Movement Analysis (IMA) to follow up suspected aseptic loosening when the diagnosis after an initial X-ray is not conclusive, compared with a diagnostic p...

    Authors: Davide Lovera, Olof Sandberg, Maziar Mohaddes and Hanna Gyllensten
    Citation: Cost Effectiveness and Resource Allocation 2023 21:88
  21. Demonstrating safety and efficacy of new medical treatments requires clinical trials but clinical trials are costly and may not provide value proportionate to their costs. As most health systems have limited r...

    Authors: Piers Gillett, Robert K Mahar, Nancy R Tran, Mark Rosenthal and Maarten IJzerman
    Citation: Cost Effectiveness and Resource Allocation 2023 21:87
  22. Breast cancer represents the most prevalent cancer among Swedish women. Although considerable research has investigated the cost-effectiveness of emerging innovative medical treatments for breast cancer, studi...

    Authors: Phu Duy Pham, Muchandifunga Trust Muchadeyi and Lars Lindholm
    Citation: Cost Effectiveness and Resource Allocation 2023 21:86
  23. Management of COVID-19 patients with mild and moderate symptoms could be isolated at home isolation (HI), community isolation (CI) or hospitel. However, it was still unclear which strategy was more cost-effect...

    Authors: Unyaporn Suthutvoravut, Patratorn Kunakorntham, Anchisatha Semayai, Amarit Tansawet, Oraluck Pattanaprateep, Pongsathorn Piebpien, Pawin Numthavaj, Ammarin Thakkinstian and Pongsakorn Atiksawedparit
    Citation: Cost Effectiveness and Resource Allocation 2023 21:85
  24. Prostate cancer is the second most common cancer in males worldwide and the third most common among Iran’s male population. However, there is a lack of evidence regarding its direct and indirect costs in low a...

    Authors: Farbod Alinezhad, Farhad Khalili, Hossein Zare, Chunling Lu, Zahra Mahmoudi and Mahmood Yousefi
    Citation: Cost Effectiveness and Resource Allocation 2023 21:84
  25. Artificial Intelligence (AI) represents a significant advancement in technology, and it is crucial for policymakers to incorporate AI thinking into policies and to fully explore, analyze and utilize massive da...

    Authors: Maryam Ramezani, Amirhossein Takian, Ahad Bakhtiari, Hamid R. Rabiee, Ali Akbar Fazaeli and Saharnaz Sazgarnejad
    Citation: Cost Effectiveness and Resource Allocation 2023 21:83
  26. In recent years, numerous guidelines and expert consensus have recommended the inclusion of digital technologies and products in cardiac rehabilitation. Digital therapeutics (DTx) is an evidence-based medicine...

    Authors: Tianyi Liu, Yiyang Zhan, Silei Chen, Wenhong Zhang and Jian Jia
    Citation: Cost Effectiveness and Resource Allocation 2023 21:82
  27. Chronic Kidney Disease (CKD) patients often require long-term care, and while Hemodialysis (HD) is the standard treatment, Comprehensive Conservative Care (CCC) is gaining popularity as an alternative. Economi...

    Authors: Telma Zahirian Moghadam, Jane Powell, Afshan Sharghi and Hamed Zandian
    Citation: Cost Effectiveness and Resource Allocation 2023 21:81
  28. Monetizing health has sparked controversy and has implications for pricing strategies of emerging health technologies. Medical insurance payers typically set up thresholds for quality-adjusted life years (QALY...

    Authors: Qian Peng, Yue Yin, Min Liang, Mingye Zhao, Taihang Shao, Yaqian Tang, Zhiqing Mei, Hao Li and Wenxi Tang
    Citation: Cost Effectiveness and Resource Allocation 2023 21:80
  29. In recent years, international academics recognized that quality-adjusted life-years (QALYs) may not always fully capture the benefits produced by an intervention, and considered incorporating additional eleme...

    Authors: Lihua Sun, Shiqi Li and Xiaochen Peng
    Citation: Cost Effectiveness and Resource Allocation 2023 21:79
  30. Dealing with randomness is a crucial aspect that cost-effectiveness analysis (CEA) tools need to address, but existing stochastic CEA tools have rarely examined risk and return from the perspective of populati...

    Authors: Ermo Chen
    Citation: Cost Effectiveness and Resource Allocation 2023 21:78
  31. Hip fractures are a common and costly health problem, resulting in significant morbidity and mortality, as well as high costs for healthcare systems, especially for the elderly. Implementing surgical preventiv...

    Authors: Momin S. Alnemer, Konstantin E. Kotliar, Valentin Neuhaus, Hans-Christoph Pape and Bernhard D. Ciritsis
    Citation: Cost Effectiveness and Resource Allocation 2023 21:77
  32. The increasing global prevalence of atrial fibrillation (AF) has led to a growing demand for stroke prevention strategies, resulting in higher healthcare costs. High-quality economic evaluations of stroke prev...

    Authors: Sumudu A. Hewage, Rini Noviyani, David Brain, Pakhi Sharma, William Parsonage, Steven M. McPhail, Adrian Barnett and Sanjeewa Kularatna
    Citation: Cost Effectiveness and Resource Allocation 2023 21:76
  33. Countries around the world are increasingly rethinking the design of their health benefit package to achieve universal health coverage. Countries can periodically revise their packages on the basis of sectoral...

    Authors: Rob Baltussen, Gavin Surgey, Anna Vassall, Ole F. Norheim, Kalipso Chalkidou, Sameen Siddiqi, Mojtaba Nouhi, Sitaporn Youngkong, Maarten Jansen, Leon Bijlmakers and Wija Oortwijn
    Citation: Cost Effectiveness and Resource Allocation 2023 21:75
  34. Authors: Richard Niehaus, Alisa Schleicher, Ammann Elias, Philipp Kriechling, Christopher G. Lenz, Michael Masanneck, Sandro Hodel and Karim Eid
    Citation: Cost Effectiveness and Resource Allocation 2023 21:74

    The original article was published in Cost Effectiveness and Resource Allocation 2023 21:63

  35. Because of a change of government, the Colombian Ministry of Health and Social Protection is in the process of presenting a structural reform for the General System of Social Security in Health (GSSSH), in ord...

    Authors: Oscar Espinosa, Jhonathan Rodríguez, B. Piedad Urdinola, Pedro Luis Do Nascimento Silva, Alejandra Sánchez, Martha-Liliana Arias, Emiliano A. Valdez, Terence Cheng and Sara-Ellison Fisher
    Citation: Cost Effectiveness and Resource Allocation 2023 21:73
  36. The Covid-19 pandemic has had serious medical, administrative and financial effects on the health system and hospitals around the world. In Türkiye, compared to 2019 realizations, in 2020 and 2021 respectively...

    Authors: Seher Nur Sülkü, Alper Mortaş and Aziz Küçük
    Citation: Cost Effectiveness and Resource Allocation 2023 21:70
  37. The global increase in mean body mass index has resulted in a substantial increase of non-communicable diseases (NCDs), including in many low- and middle-income countries such as Kenya. This paper assesses fou...

    Authors: Mary Njeri Wanjau, Lucy W. Kivuti-Bitok, Leopold N. Aminde and J. Lennert Veerman
    Citation: Cost Effectiveness and Resource Allocation 2023 21:69
  38. Tuberculosis (TB) is a communicable disease that is a major cause of death and one of the leading causes of death worldwide. Currently, there is no analyzed data to examine the financial profile of TB by count...

    Authors: Maryam Meskini, Nahid Madadi, Kamal Ahmadi, Farzam Vaziri, Abolfazl Fateh and Seyed Davar Siadat
    Citation: Cost Effectiveness and Resource Allocation 2023 21:68
  39. The use of peripherally inserted central catheters and midline catheters is growing due to their potential benefits. These devices can increase patient safety and satisfaction while reducing the use of resourc...

    Authors: Laura Ricou Ríos, Candela Esposito Català, Arnau Pons Calsapeu, Cristina Adroher Mas, Isabel Andrés Martínez, Isaac Nuño Ruiz, Mònica Castellà Creus, Laia Castellà Fàbregas, Maria José García Quesada, Oriol Estrada Cuxart, Jordi Ara del Rey and Francesc López Seguí
    Citation: Cost Effectiveness and Resource Allocation 2023 21:67
  40. In an effort to minimize positive margins and subsequent re-excision after breast conserving surgery (BCS), many providers and facilities have implemented either a Full Cavity Shave (FCS) approach or adding th...

    Authors: Richard Gilmore, Jennifer Chen, Robert Dembinski, Yannis Reissis, David Milek, Lisa Cadena and Mehran Habibi
    Citation: Cost Effectiveness and Resource Allocation 2023 21:66
  41. The aim of the study was to evaluate the cost-effectiveness of nivolumab plus chemotherapy as first-line treatment for patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal adenocarcin...

    Authors: Peng-Fei Zhang, Xuan-Qiong Shi and Qiu Li
    Citation: Cost Effectiveness and Resource Allocation 2023 21:65
  42. Acromioclavicular joint dislocations (ACD) are one of the most common shoulder injuries. There is no consensus in how to treat higher graded ACD ≥ Rockwood grade III. This study compares operative versus conse...

    Authors: Richard Niehaus, Alisa Schleicher, Elias Ammann, Philipp Kriechling, Christopher G. Lenz, Michael Masanneck, Sandro Hodel and Karim Eid
    Citation: Cost Effectiveness and Resource Allocation 2023 21:63

    The Correction to this article has been published in Cost Effectiveness and Resource Allocation 2023 21:74

  43. Cost-effectiveness analysis (CEA) is a standard tool for evaluating health programs and informing decisions about resource allocation and prioritization. Most CEAs evaluating health interventions in low- and m...

    Authors: Joseph Corlis, Jinyi Zhu, Hélder Macul, Orrin Tiberi, Makini A. S. Boothe and Stephen C. Resch
    Citation: Cost Effectiveness and Resource Allocation 2023 21:62

Annual Journal Metrics

  • 2022 Citation Impact
    2.3 - 2-year Impact Factor
    2.4 - 5-year Impact Factor
    0.916 - SNIP (Source Normalized Impact per Paper)
    0.530 - SJR (SCImago Journal Rank)

    2022 Speed
    8 days submission to first editorial decision for all manuscripts (Median)
    189 days submission to accept (Median)

    2022 Usage 
    431,165 downloads
    2,114 Altmetric mentions